Harvard Bioscience (HBIO) vs Utah Medical Products (UTMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Utah Medical Products (UTMD) over the past year, gaining 84.8% versus a gain of 16.5%. Over five years, UTMD leads with a -17.9% price change compared with -88.1% for HBIO. Utah Medical Products is the larger company by market cap ($236.6 million vs $37.5 million), about 6.3 times the size.
Utah Medical Products pays a dividend yielding 1.66%, while Harvard Bioscience does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | UTMD |
|---|---|---|
| Share price | $8.24 | $74.54 |
| Market cap | $37.51M | $236.58M |
| 1-day change | +1.35% | +0.90% |
| YTD return | +21.34% | +32.01% |
| 1-year return | +84.77% | +16.47% |
| 5-year return | -88.11% | -17.93% |
| P/E ratio (TTM) | — | 22.73 |
| Forward P/E | 12.78 | — |
| EPS (TTM) | $-2.31 | $3.28 |
| Dividend yield | 0.00% | 1.66% |
| Annual dividend | $0.00 | $1.24 |
| 52-week high | $9.40 | $76.89 |
| 52-week low | $3.80 | $53.66 |
| Distance from 52-week high | -12.34% | -3.06% |
| Analyst consensus | none | — |
| Avg. price target upside | -8.98% | — |
| Average volume | 17.98K | 34.56K |
| Shares outstanding | 4.55M | 3.17M |
| Employees | 316 | 140 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Utah Medical Products is about 6.3 times larger than Harvard Bioscience by market value ($236.58M vs $37.51M).
- HBIO has outperformed UTMD by 68.3 percentage points over the past year.
- Utah Medical Products offers a meaningfully higher dividend yield (1.66% vs 0.00%).
- The two companies sit in different sectors: Harvard Bioscience in Industrials and Utah Medical Products in Health Care.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Utah Medical Products
UTMD stock →Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally.
Health Care · Medical/Dental Instruments · 140 employees
HBIO vs UTMD FAQ
Which is bigger, Harvard Bioscience or Utah Medical Products?
Utah Medical Products (UTMD) is larger, with a market capitalization of $236.58M compared with $37.51M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or UTMD?
HBIO returned +84.77% over the past 12 months, compared with +16.47% for UTMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Harvard Bioscience or Utah Medical Products?
Utah Medical Products pays a dividend yielding 1.66%, while Harvard Bioscience does not currently pay a regular dividend.
Are Harvard Bioscience and Utah Medical Products in the same industry?
No. Harvard Bioscience is in the Industrials sector, while Utah Medical Products is in Health Care.